Risk factors for acquired drug-resistant tuberculosis Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Effectiveness of the WHO regimen for treatment of multidrug resistant tuberculosis (MDR-TB) Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Range of additional drug resistance of M.tuberculosis in XDR-TB patients Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Spectrum of adverse drug reactions during MDR TB treatment Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Evaluation of drug induced liver injury due to anti tuberculous drugs in directly observed daily therapy Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Impact of drug injection using on TB-AIDS treatment outcomes Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management I Year: 2013
Drug resistant tuberculosis at a drug resistant tuberculosis centre, India- Analysis of outcome Source: International Congress 2017 – TB: co-morbidities and outcome Year: 2017
Side effects of chemical preparations in patients with drug-resistant pulmonary tuberculosis Source: International Congress 2015 – Healthcare organisation and appropriateness in lung disorders Year: 2015
Effect of diabetes mellitus on the Time of mycobacterial clearance from sputum during the treatment of multi-drugs resistant tuberculosis Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2 Year: 2014
Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015
Treatment by linezolid of lung TB caused by drug resistant mycobacterium (MBT) Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Spread of tuberculosis among household contacts of multi drug resistant tuberculosis (MDRTB) patients Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014
Restarting biologic agents in rheumatology patients who developed tuberculosis under TNFα-inhibitor treatment Source: International Congress 2015 – Latent TB infection and screening Year: 2015
The effectiveness of pulmonary TB treatment in patients with organic liver diseases, depending on the way of administration of anti-TB drugs Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Predictive factors of a delayed culture conversion under tuberculosis treatment Source: Annual Congress 2013 –Tuberculosis diagnosis Year: 2013
Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
MOTT as a cause of treatment failure in pulmonary tuberculosis Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013
Side effect profile of 2nd line drugs in multi drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015